Frankfurt
30.04.26 | 08:12
0,086 Euro
-1,61 % -0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | AlzeCure Pharma: Adjusted Timeline for the Previously Communicated Rights Issue | 364 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 30, 2026 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a biotech company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| Do | AlzeCure Pharma AB: Adjusted timeline for the previously communicated rights issue | 73 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, announces that the timeline... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.04.2026 | 250 | Xetra Newsboard | Das Instrument FWR0 CA98873A1057 YUMY CANDY COMPANY INC. EQUITY wird cum Kapitalmassnahme gehandelt am 29.04.2026 und ex Kapitalmassnahme am 30.04.2026 The instrument FWR0 CA98873A1057 YUMY CANDY COMPANY... ► Artikel lesen | |
| 24.04. | AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million | 93 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 24.04. | AlzeCure Pharma AB: AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million | 138 | GlobeNewswire (Europe) | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 20.04. | AlzeCure Pharma: Last Patient has Completed AlzeCure's Phase Ib Clinical Study with NeuroRestore ACD856 | 323 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 20, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 20.04. | AlzeCure Pharma AB: Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856 | 224 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that... ► Artikel lesen | |
| 08.04. | AlzeCure Pharma Publishes its Annual Report for 2025 | 274 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 8, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 07.04. | AlzeCure Pharma to Present at Redeye Healthcare Day on April 14 | 287 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 7, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 01.04. | AlzeCure Pharma to Present at Redeye Alzheimer's Theme Event on April 9 | 249 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 19.03. | AlzeCure Pharma: AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer's Conference AD/PD | 457 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system,... ► Artikel lesen | |
| 04.03. | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11 | 319 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 4, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 26.02. | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2025 | 410 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now available... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: Pain Project ACD440 Granted Orphan Drug Status in the EU | 907 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 24, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous... ► Artikel lesen | |
| 03.02. | AlzeCure Pharma: AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026 | 808 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| 02.02. | AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam | 1.162 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 2, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 03.12.25 | AlzeCure Pharma: AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer's Disease | 435 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / December 3, 2025 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system... ► Artikel lesen | |
| 11.11.25 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2025 | 334 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January... ► Artikel lesen | |
| 14.10.25 | AlzeCure Pharma: Response Letter to Previous Article Published about Alzstatin's Unique Mode of Action Against Alzheimer's | 672 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / October 14, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| 08.09.25 | AlzeCure Pharma: Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025 | 414 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 8, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 367,60 | +0,93 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| VIATRIS | 12,728 | -0,06 % | Viatris presents data on low-dose contraceptive patch at ACOG | ||
| ALTIMMUNE | 2,220 | +0,68 % | Altimmune schließt Finanzierung über 225 Mio. US-Dollar für MASH-Medikament ab | ||
| OPKO HEALTH | 0,890 | -7,29 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,240 | +0,71 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| JAGUAR HEALTH | 0,000 | -99,92 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA7481197084 Quebec Nickel Corp. 29.04.2026 CA0515341059 Aurbis Resources Corp. 30.04.2026 Tausch 1:1CA89620A5061 Trigon... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,260 | +1,14 % | Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right | ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 3,882 | +5,09 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces ... | - Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,350 | -0,42 % | Kiora Pharmaceuticals, Inc.: Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway | Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature... ► Artikel lesen | |
| LIPOCINE | 2,350 | +2,62 % | Lipocine Inc.: Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression | In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score... ► Artikel lesen | |
| PHOTOCURE | 5,890 | -3,12 % | PHOTOCURE: Photocure ASA: Invitation to presentation of first quarter 2026 financial results | ||
| EUROBIO SCIENTIFIC | 22,800 | 0,00 % | Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division | EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's 'lab products' portfolio creates new opportunities for growth and innovation... ► Artikel lesen | |
| MEDICURE | 0,640 | +11,30 % | Medicure, Inc.: Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference Call | WINNIPEG, MB / ACCESS Newswire / April 23, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and... ► Artikel lesen | |
| BAYER | 38,050 | +4,39 % | SCHOCK und CHANCE: Nel ASA, K+S und Bayer-Partner MustGrow! Welche Aktie überzeugt? | Wann startet endlich die Aktie von MustGrow durch? Eigentlich kann dies nur eine Frage der Zeit sein. Die Kanadier ersetzen konventionellen Dünger durch Senf. In den USA hat man bereits Zulassungen... ► Artikel lesen | |
| MERCK KGAA | 110,05 | +1,71 % | Eli Lilly, Roche und Merck dominieren - Mesoblast startet kommerzielle Phase |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,61 % bei einem Aktienkurs von 0,086 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.